SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized SpaceX asset while simultaneously analyzing the broader implications of an expected SpaceX IPO. The community is heavily focused on identifying proxy stocks and potential pump-and-dump risks as speculative excitement builds around the aerospace sector.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is drawing attention as community members focus on its institutional-grade interoperability and potential role in upcoming bank-led tokenized asset pilots. While some investors remain cautious, many are actively accumulating during price consolidations, citing the token's scarcity and long-term utility as reasons to hold despite broader market volatility.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is experiencing a surge in social sentiment driven by its privacy features and growing institutional interest, including reports of significant accumulation by corporate entities. Investors are actively debating its potential as a 'quantum-safe' alternative to Bitcoin, with many community members highlighting the upcoming Clarity Act as a major catalyst for long-term growth.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement with Japan BCG Laboratory, a strategic move aimed at resolving the critical domestic BCG shortage and undermining the monopoly held by established suppliers. The community is actively discussing this as a major catalyst that strengthens ANKTIVA's commercial outlook, with investors eagerly anticipating further scientific updates at the American Urological Association annual meeting.

Pop Cat refers to a series of videos in which using an image of a cat named Oatmeal, the cat is photoshopped as if it's opening its mouth wide in an O shape.

Popcat

Popcat is currently trending as investors debate the sustainability of its price action and compare its momentum to other popular cat-themed meme coins in the Solana ecosystem. Community sentiment remains highly divided, with many traders accumulating on dips while others express frustration over the token's recent volatility and its lagging performance relative to broader market moves.

Direxion Shares ETF Trust - Direxion Daily 20+ Year Treasury Bull 3X Shares

Direxion Daily 20+ Year Treasury Bull 3X Shares

TMF is trending as investors aggressively debate the future of long-term interest rates, with the community split between those betting on a recession-driven rate collapse and others shorting the asset due to persistent inflationary pressures and elevated bond yields. Sentiment remains heavily polarized as traders weigh the impact of potential fiscal policy shifts and labor market weakness against the ongoing struggle of leveraged bond ETFs to gain traction.

Planet Fitness, Inc. engages in the operation and franchising of fitness centers. It operates through the following segments: Franchise, Corporate-Owned Clubs, and Equipment. The Franchise segment includes operations related to the company's franchising business in the United States, Puerto Rico, Canada, Panama, Mexico, and Australia. The Corporate-Owned Clubs segment consists of operations with respect to all corporate-owned clubs throughout the United States, Canada, and Spain. The Equipment segment involves the sale of equipment to franchisee-owned clubs in the United States, Canada, and Mexico. The company was founded by Michael Grondahl and Marc Grondahl in 1992 and is headquartered in Hampton, NH.

Planet Fitness Inc - Ordinary Shares - Class A

Planet Fitness is currently at the center of investor focus as the company navigates a combination of weaker-than-expected growth guidance and significant insider buying. While the community is actively debating the company's recent marketing missteps and the intensifying competitive landscape in the budget-gym segment, market participants are split between those viewing the pullback as a buying opportunity and others concerned about long-term member retention.

Zepp Health Corp. engages in the development of smart wearable health and consumer fitness devices. It empowers users to achieve their well-being goals by optimizing their health, fitness, and wellness journeys. Its brands include Amazfit, Zepp Clarity, and Zepp Aura. The company was founded by Huang Wang in 2013 and is headquartered in Gorinchem, Netherlands.

Zepp Health Corporation - ADR

Huami Corp

Huami Corp is trending as investors weigh its rapid, momentum-driven price surge against questions about the sustainability of its growth and competitive positioning in the wearables market. Community members are actively debating the company's long-term valuation potential versus concerns regarding its business fundamentals, recent product lineup fragmentation, and heavy institutional accumulation.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies is drawing significant investor interest as a low-float play positioned within the domestic rare earth supply chain. While some users are betting on the company's tech-integrated mining approach to disrupt the sector, others are cautious of intense price volatility and concerns regarding heavy insider control.

JBS NV is a food company that engages in the sale of beef, pork, lamb meat and poultry products. It offers its products to supermarkets, club stores, other retail distributors, and foodservice companies. The company was founded on October 9, 2019 and is headquartered in Amstelveen, the Netherlands.

JBS N.V. - Ordinary Shares - Class A

JBS is trending as investors monitor the company's evolving strategy to capture demand for high-value protein and functional nutrition in the face of shifting consumer trends. The community is actively debating the stock's valuation relative to its industry peers, the potential impact of dividend payouts, and the company's broader positioning within global food markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Pulmatrix Announces First Quarter 2026 Financial Results

Pulmatrix Announces First Quarter 2026 Financial Results Pulmatrix Announces First Quarter 2026 Financial Results PR Newswire FRAMINGHAM, Mass., May 15, 2026 Announced merger agreement with Eos...

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger PR Newswire FRAMINGHAM...

PULM Stock Alert: Halper Sadeh LLC is Investigating Whether Pulmatrix, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Pulmatrix, Inc. (NASDAQ: PULM) and Eos SENOLYTIX, Inc. Upon closing of the proposed transaction, Pulmatrix stockholders...

Pulmatrix To Acquire Eos Senolytix In Merger

(RTTNews) - Pulmatrix Inc. (PULM), a clinical-stage biopharmaceutical company, on Thursday announced that it has entered into a definitive agreement to acquire Eos Senolytix Inc. in a merger...

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan PR Newswire FRAMINGHAM, Mass. and HOUSTON, March 26, 2026...

<ul class="summary-bullets"><li>Gyre Therapeutics subsequently said that it has entered into an agreement to acquire Cullgen in an all-stock transaction valued at about $300 million.</li><li>Under the terms of the merger deal, Cullgen will become a wholly owned subsidiary of Gyre.</li><li>Meanwhile, Pulmatrix said that it continues to pursue alternative merger opportunities.</li></ul>Shares of Pulmatrix, Inc. (PULM), slumped 36% on Monday after the company said that its merger agreement with privately-held pharmaceutical company Cullgen Inc has been terminated.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/pulmatrix-announces-termination-of-prior-planned-merger-and-continues-pursuit-of-alternative-merger-opportunities-302700613.html">said</a> that Cullgen notified it of the deal termination on Feb. 28. The two companies had entered a merger deal in November 2024 and modified it in December 2025 to allow each party to explore alternate transactions. The company added that it did not receive necessary approval from China Security Regulatory Commission for the deal at the time of Cullgen’s agreement termination.Gyre Therapeutics, Inc. (GYRE) subsequently <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/03/02/3247348/0/en/Gyre-Therapeutics-Enters-into-Agreement-to-Acquire-Cullgen-to-Gain-Targeted-Protein-Degradation-Platform-and-Pipeline.html">said</a> that it has entered into an agreement to acquire Cullgen in an all-stock transaction valued at about $300 million.<h2 class="st-heading-2">Gyre-Cullgen Deal</h2>Cullgen is focused on the discovery and development of targeted protein degrader (TPD) and degrader antibody conjugate (DAC) therapies. &nbsp;Under the terms of the merger deal, Cullgen will become a wholly owned subsidiary of Gyre.The transaction is expected to close early in the second quarter of 2026, subject to customary closing conditions, including necessary regulatory approvals in the U.S.Following the closure of the acquisition, the new combined entity will be a fully integrated biopharmaceutical company with U.S.- and China-based capabilities spanning from discovery to manufacturing and commercialization and covering multiple therapeutic areas including inflammatory diseases, cancers, and pain, the company said.Shares of GYRE rallied 8% at the time of writing.<h2 class="st-heading-2">Path Ahead For Pulmatrix</h2>Meanwhile, Pulmatrix said that it continues to pursue alternative merger opportunities."Due to the significant delays at the Chinese Regulatory Authority (CSRC) in 2025, we initiated a process earlier this year to identify an alternative reverse merger opportunity for the Company, and we are encouraged by both the interest we've had to date as well as the recent increase in transaction activity within our industry," the company’s interim CEO Peter Ludlum said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around GYRE rose from ‘Neutral’ to ‘Bullish’ territory over the past 24 hours, while message volume remained at ‘Normal’ levels.Meanwhile, sentiment around PULM stayed ‘bullish,’ accompanied by ‘high’ message volume.<a href="https://stocktwits.com/symbol/GYRE">Shares of GYRE</a> lost 22% over the past 12 months. <a href="https://stocktwits.com/symbol/PULM">PULM stock</a> dipped 75% in the meantime.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tlry-stock-slumps-whats-driving-the-sell-off/cZd3gYYRI27">TLRY Stock Slumps 4%: What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Gyre Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead

Pulmatrix said that Cullgen notified it of the termination of the deal between them on Feb. 28.

Equity

Pulmatrix said that Cullgen notified it of the termination of the deal between them on Feb. 28.


Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of...

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results PR Newswire FRAMINGHAM, Mass., Feb. 26, 2026 Plans to...

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for...

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.

PULM
Pulmatrix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PULM News

PULMPulmatrix Inc